ENTITY

Stille (STIL SF)

12
Analysis
Health Care • Sweden
Stille AB is a Sweden-based company that develops, manufactures, and markets medical devices. The company operates through two business segments: Surgical Instruments and Surgical Tables. The Surgical Instruments segment provides a variety of handcrafted, forged surgical instruments for open surgery, with a focus on cardiovascular, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, clamps, and retractors. The Surgical Tables segment, also referred to as Patient Positioning, develops and manufactures specialized procedure-specific tables for cardiovascular surgery, gynecology, and urology.
more
bullish•Stille
•24 Apr 2026 14:54•Syndicated

Stille (Q1 initial take): Starting the year with a slam dunk despite FX-headwind

Q1 delivered a broad beat versus our estimates with 19% organic growth and EBITDA 25% above our forecast, despite FX headwinds of ~SEK10m, we...

Logo
Redeye
113 Views
Share
bullish•Stille
•22 Apr 2026 17:14•Syndicated

Stille (Q1 preview): Navigating headwind, expecting a solid report

Redeye expects a sequential decline against the exceptionally strong Q4, but continued double-digit YoY growth and an EBITDA margin of around 20%,...

Logo
Redeye
94 Views
Share
bullish•Stille
•13 Feb 2026 15:05•Syndicated

Stille: (Q4 review): Easing headwinds and solid outlook at 11x current year EV/EBITDA

Stille’s soft share price development over the past months to us appears more sentiment-driven than fundamental following the Q4 report. With...

Logo
Redeye
87 Views
Share
bullish•Stille
•12 Feb 2026 16:39•Syndicated

Stille (Q4 initial take): Beat across the board despite FX headwinds

Redeye's immediate impression of Stille's year-end report 2025 is positive. Despite fx-headwind the company beat our projections across the...

Logo
Redeye
85 Views
Share
bearish•Stille
•27 Oct 2025 15:02•Syndicated

Stille (Q3 Review): Prolonged headwind but valuation remains undemanding

Redeye provides an updated view of Stille following the Q3 2025 report. Amid prolonged supply chain constraints, FX headwinds, and the phase-out...

Logo
Redeye
88 Views
Share
x